Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

Legend Biotech ( LEGN +18.42%) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...

Biotech and pharma companies are accelerating adoption of non-animal testing methods such as organs-on-a-chip, computational models, and organoids to improve human-relevant drug development. This ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.